Milestone
Domain Therapeutics SA, of Strasbourg, France, a discovery company specialising in G Protein-Coupled Receptors (GPCRs) drug targets has announced that it has successfully completed the first milestone in its research agreement with Takeda Pharmaceuticals, triggering a milestone payment.
The research agreement covers the use of Domain’s DTect-All technology for the discovery of candidates for GPCRs of interest to Takeda.
Although they are very important drug targets, GPCRs are not easy to crystallise and are notoriously difficult to handle and manipulate.
“Achievement of this milestone is a confirmation of the ability of Domain Therapeutics’ technology to address difficult GPCRs,” said Pascal Neuville, CEO.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
